What happened
Waters Corp. has introduced a new AI-powered integration called Peak Integration into its Empower software platform. This integration uses artificial intelligence and machine learning capabilities to reduce manual interventions in drug discovery and manufacturing. According to Waters, the new AI feature can reduce manual interventions by 95%, improve testing accuracy by 76%, and is 50% faster than the prior process.
Waters Corp. has introduced a new AI-powered integration called Peak Integration into its Empower software platform.
The new AI feature uses artificial intelligence and machine learning capabilities to reduce manual interventions in drug discovery and manufacturing.
According to Waters, the new AI feature can reduce manual interventions by 95%, improve testing accuracy by 76%, and is 50% faster than the prior process.
The new AI feature is the second major AI feature that Waters has announced for Empower, following an AI/ML anomaly detection tool that debuted in February 2025.
Waters worked closely with a top-ten pharmaceutical company for about one-and-a-half years to develop the new AI feature, securing legal agreements and guaranteeing safe data exchange processes.
Why it matters
The new AI feature has the potential to accelerate drug discovery and reduce the $2 trillion, 10-year process of getting medicines approved and into the market. It can also improve the quality and safety of medicines by reducing manual errors and improving testing accuracy.
The new AI feature has the potential to accelerate drug discovery and reduce the $2 trillion, 10-year process of getting medicines approved and into the market.
It can also improve the quality and safety of medicines by reducing manual errors and improving testing accuracy.
The new AI feature is part of Waters' efforts to increase the use of AI in its operations, including the integration of a biosciences and diagnostics solutions business that it acquired from Becton Dickinson.
Waters' chief information officer, Brook Colangelo, has been a proponent of AI adoption in the pharmaceutical industry, citing its potential to improve efficiency and reduce costs.
Colangelo has also emphasized the importance of developing AI-powered tools that can help scientists focus on more complex and creative tasks, rather than repetitive and mundane ones.
Interactive Mechanism: How It Actually Works
Explore the underlying technology behind this development interactively.
A route planner searches possible journeys using explicit rules. What does this illustrate about AI?
What to watch next
The impact of the new AI feature on the pharmaceutical industry, the potential for increased adoption of AI in drug discovery and manufacturing, and the development of more advanced AI-powered tools for quality control and assurance.
The impact of the new AI feature on the pharmaceutical industry, including its potential to accelerate drug discovery and improve the quality and safety of medicines.
The potential for increased adoption of AI in drug discovery and manufacturing, including the development of more advanced AI-powered tools for quality control and assurance.
The development of more advanced AI-powered tools for quality control and assurance, including the use of machine learning and natural language processing.
The potential for AI to improve the efficiency and reduce the costs of pharmaceutical research and development, including the use of AI-powered tools for data analysis and visualization.
The development of more advanced AI-powered tools for quality control and assurance, including the use of blockchain and other emerging technologies.